ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Sold by Squarepoint Ops LLC

Squarepoint Ops LLC cut its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 67.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 185,313 shares of the biopharmaceutical company's stock after selling 387,577 shares during the period. Squarepoint Ops LLC owned 0.11% of ACADIA Pharmaceuticals worth $3,400,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of the business. Barclays PLC increased its holdings in shares of ACADIA Pharmaceuticals by 126.2% in the 3rd quarter. Barclays PLC now owns 277,565 shares of the biopharmaceutical company's stock valued at $4,269,000 after acquiring an additional 154,854 shares during the period. Proficio Capital Partners LLC acquired a new position in shares of ACADIA Pharmaceuticals in the 4th quarter valued at $272,000. Vanguard Group Inc. boosted its position in ACADIA Pharmaceuticals by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 13,947,640 shares of the biopharmaceutical company's stock valued at $255,939,000 after buying an additional 104,444 shares during the last quarter. Victory Capital Management Inc. raised its holdings in shares of ACADIA Pharmaceuticals by 66.9% during the fourth quarter. Victory Capital Management Inc. now owns 162,125 shares of the biopharmaceutical company's stock worth $2,975,000 after purchasing an additional 64,995 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its holdings in shares of ACADIA Pharmaceuticals by 10.9% in the 4th quarter. Principal Financial Group Inc. now owns 143,694 shares of the biopharmaceutical company's stock valued at $2,637,000 after buying an additional 14,143 shares during the period. Hedge funds and other institutional investors own 96.71% of the company's stock.

ACADIA Pharmaceuticals Trading Down 2.7%

Shares of NASDAQ ACAD traded down $0.60 during trading hours on Friday, reaching $21.69. The stock had a trading volume of 778,387 shares, compared to its average volume of 1,931,196. The firm has a 50-day moving average of $16.78 and a 200-day moving average of $17.45. The firm has a market cap of $3.63 billion, a price-to-earnings ratio of 27.80 and a beta of 0.47. ACADIA Pharmaceuticals Inc. has a fifty-two week low of $13.40 and a fifty-two week high of $25.23.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of $0.10 by $0.01. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. The firm had revenue of $244.32 million during the quarter, compared to the consensus estimate of $239.32 million. During the same quarter last year, the firm earned $0.10 earnings per share. The firm's revenue was up 18.7% compared to the same quarter last year. On average, equities analysts predict that ACADIA Pharmaceuticals Inc. will post 0.7 EPS for the current year.

Insider Transactions at ACADIA Pharmaceuticals

In other news, Director Elizabeth A. Garofalo sold 4,919 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total value of $89,673.37. Following the sale, the director now directly owns 17,595 shares in the company, valued at $320,756.85. This represents a 21.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Mark C. Schneyer sold 3,171 shares of the company's stock in a transaction on Wednesday, March 26th. The shares were sold at an average price of $17.05, for a total value of $54,065.55. Following the completion of the sale, the executive vice president now owns 56,889 shares in the company, valued at $969,957.45. This represents a 5.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 23,746 shares of company stock valued at $428,221 in the last quarter. 28.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several analysts recently commented on the stock. Wall Street Zen upgraded shares of ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Wednesday, May 21st. Robert W. Baird upped their price objective on ACADIA Pharmaceuticals from $28.00 to $31.00 and gave the company an "outperform" rating in a report on Monday, May 19th. Cantor Fitzgerald reissued an "overweight" rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $26.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Monday, May 19th. Finally, HC Wainwright lifted their target price on ACADIA Pharmaceuticals from $27.00 to $32.00 and gave the company a "buy" rating in a research report on Monday, May 19th. Five research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $26.83.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.